These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 28977547)

  • 1. Dramatic response to alectinib in inflammatory myofibroblastic tumor with anaplastic lymphoma kinase fusion gene.
    Saiki M; Ohyanagi F; Ariyasu R; Koyama J; Sonoda T; Nishikawa S; Kitazono S; Yanagitani N; Horiike A; Ninomiya H; Ishikawa Y; Nishio M
    Jpn J Clin Oncol; 2017 Dec; 47(12):1189-1192. PubMed ID: 28977547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FN1: a novel fusion partner of ALK in an inflammatory myofibroblastic tumor.
    Ouchi K; Miyachi M; Tsuma Y; Tsuchiya K; Iehara T; Konishi E; Yanagisawa A; Hosoi H
    Pediatr Blood Cancer; 2015 May; 62(5):909-11. PubMed ID: 25682942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report.
    Honda K; Kadowaki S; Kato K; Hanai N; Hasegawa Y; Yatabe Y; Muro K
    Invest New Drugs; 2019 Aug; 37(4):791-795. PubMed ID: 30790150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor.
    Cools J; Wlodarska I; Somers R; Mentens N; Pedeutour F; Maes B; De Wolf-Peeters C; Pauwels P; Hagemeijer A; Marynen P
    Genes Chromosomes Cancer; 2002 Aug; 34(4):354-62. PubMed ID: 12112524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fusion of dynactin 1 to anaplastic lymphoma kinase in inflammatory myofibroblastic tumor.
    Wang X; Krishnan C; Nguyen EP; Meyer KJ; Oliveira JL; Yang P; Yi ES; Erickson-Johnson MR; Yaszemski MJ; Maran A; Oliveira AM
    Hum Pathol; 2012 Nov; 43(11):2047-52. PubMed ID: 22658521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status.
    Tanaka H; Taima K; Morimoto T; Nakamura K; Tanaka Y; Itoga M; Takanashi S; Okumura K
    BMC Res Notes; 2016 Mar; 9():173. PubMed ID: 26987388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory myofibroblastic tumor with predominant anaplastic lymphoma kinase-positive cells lacking a myofibroblastic phenotype.
    Hisaoka M; Shimajiri S; Matsuki Y; Meis-Kindblom JM; Kindblom LG; Li XQ; Wang J; Hashimoto H
    Pathol Int; 2003 Jun; 53(6):376-81. PubMed ID: 12787312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification.
    Takeuchi K; Soda M; Togashi Y; Sugawara E; Hatano S; Asaka R; Okumura S; Nakagawa K; Mano H; Ishikawa Y
    Clin Cancer Res; 2011 May; 17(10):3341-8. PubMed ID: 21430068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
    Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA
    J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non-Small-Cell Lung Cancer: A┬áRetrospective Analysis.
    Asao T; Fujiwara Y; Itahashi K; Kitahara S; Goto Y; Horinouchi H; Kanda S; Nokihara H; Yamamoto N; Takahashi K; Ohe Y
    Clin Lung Cancer; 2017 Jul; 18(4):e251-e258. PubMed ID: 28065466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor.
    Bridge JA; Kanamori M; Ma Z; Pickering D; Hill DA; Lydiatt W; Lui MY; Colleoni GW; Antonescu CR; Ladanyi M; Morris SW
    Am J Pathol; 2001 Aug; 159(2):411-5. PubMed ID: 11485898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraosseous inflammatory myofibroblastic tumor of the mandible with a novel ATIC-ALK fusion mutation: a case report.
    Tateishi Y; Okudela K; Kawai S; Suzuki T; Umeda S; Matsumura M; Kioi M; Ohashi K
    Diagn Pathol; 2016 Nov; 11(1):132. PubMed ID: 27846861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer.
    Hui B; Zhang J; Shi X; Xing F; Shao YW; Wang Y; Zhang X; Wang S
    Jpn J Clin Oncol; 2020 Dec; 50(12):1470-1474. PubMed ID: 32845005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid and dramatic response to alectinib in an anaplastic lymphoma kinase rearranged non-small-cell lung cancer patient who is critically ill.
    Yoshida T; Hida T; Yatabe Y
    Anticancer Drugs; 2016 Jul; 27(6):573-5. PubMed ID: 26938871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors.
    Lawrence B; Perez-Atayde A; Hibbard MK; Rubin BP; Dal Cin P; Pinkus JL; Pinkus GS; Xiao S; Yi ES; Fletcher CD; Fletcher JA
    Am J Pathol; 2000 Aug; 157(2):377-84. PubMed ID: 10934142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
    Ou SH; Greenbowe J; Khan ZU; Azada MC; Ross JS; Stevens PJ; Ali SM; Miller VA; Gitlitz B
    Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.
    Mamesaya N; Nakashima K; Naito T; Nakajima T; Endo M; Takahashi T
    BMC Cancer; 2017 Jul; 17(1):471. PubMed ID: 28683775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anaplastic lymphoma kinase-directed therapy in inflammatory myofibroblastic tumors.
    Tothova Z; Wagner AJ
    Curr Opin Oncol; 2012 Jul; 24(4):409-13. PubMed ID: 22664824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel KIF5B-ALK fusion in a child with an atypical central nervous system inflammatory myofibroblastic tumour.
    Maruggi M; Malicki DM; Levy ML; Crawford JR
    BMJ Case Rep; 2018 Oct; 2018():. PubMed ID: 30344149
    [No Abstract]   [Full Text] [Related]  

  • 20. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
    Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
    Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.